10:04 AM EST - BELLUS Health Inc. : Has completed patient enrollment for the RELIEF trial, its dose-escalation, placebo-controlled Phase 2 trial of BLU-5937 in patients with refractory chronic cough. BELLUS Health Inc.
shares T.BLU are trading up $1.12 at $10.54.
